



## Chitosan-Based Hydrogels for Responsive Cancer Therapy and Immunomodulation

**Damien Masson**

*Faculty of Engineering, University of Sydney, Sydney, Australia*

### Abstract

*The paradigm of oncological treatment has increasingly shifted from systemic, non-specific chemotherapy to localized, highly targeted interventions. Among the numerous biomaterials investigated for localized drug delivery, chitosan-based hydrogels have emerged as exceptionally versatile platforms capable of both stimuli-responsive drug release and active immunomodulation. This paper provides a comprehensive academic analysis of the synthesis, mechanisms, and therapeutic applications of smart chitosan hydrogels in cancer therapy. By capitalizing on the mildly acidic, hyper-metabolic, and reductive nature of the tumor microenvironment, these intelligent biopolymer networks can be engineered to release chemotherapeutic agents with precise spatiotemporal control. Furthermore, the inherent cationic properties of chitosan serve a dual purpose, acting not merely as an inert structural scaffold but as a potent immunoadjuvant. The material demonstrates a profound ability to reprogram immunosuppressive tumor microenvironments by facilitating the maturation of dendritic cells and promoting the polarization of macrophages toward an anti-tumor phenotype. Through a detailed examination of contemporary literature, methodological synthesis strategies, and aggregated analytical results, this paper highlights the synergistic potential of combining responsive drug delivery with localized immunotherapy. The discussion also addresses the mechanical, degradative, and biocompatibility profiles of these systems, paving the way for future clinical translation in oncology.*

**Keywords :** Chitosan, Hydrogels, Immunomodulation, Cancer Therapy

## INTRODUCTION

### 1.1 Background on Cancer Therapy Challenges

Malignant neoplasms remain one of the most formidable global health challenges, contributing to immense morbidity and mortality rates worldwide [1]. Conventional treatment modalities, predominantly encompassing surgical resection, systemic chemotherapy, and external beam radiation, have historically formed the cornerstone of oncological intervention. However, the efficacy of systemic chemotherapy is severely compromised by its inherent lack of specificity. Cytotoxic agents administered intravenously distribute throughout the body, leading to collateral damage in healthy, rapidly dividing tissues [2]. This indiscriminate cytotoxicity results in severe dose-limiting side effects, including myelosuppression, gastrointestinal toxicity, and neurotoxicity, which severely diminish the patient quality of life and frequently necessitate the premature cessation of potentially curative treatments. Furthermore, the physiological architecture of solid tumors presents significant barriers to effective drug delivery. The abnormal angiogenesis characteristic of malignant growth produces a chaotic, highly permeable, yet functionally defective vascular network. While this phenomenon, known as the enhanced permeability and retention effect, was long considered a mechanism for passive targeting of nanomedicines, recent clinical data suggest its utility in human patients is highly

heterogeneous and often insufficient [3]. Compounding these vascular abnormalities is the dense extracellular matrix and lack of functional lymphatic drainage within solid tumors, which together generate an elevated interstitial fluid pressure. This pressure gradient acts as a formidable physical barrier, outward-flowing and actively preventing the deep penetration of therapeutic molecules into the tumor core. As a result, sub-lethal concentrations of drugs often reach the innermost cancer cells, creating a selective pressure that actively drives the evolution of multidrug resistance. To circumvent the limitations of systemic administration and overcome the physical barriers of the tumor architecture, localized drug delivery systems have garnered intense scientific interest. By implanting or injecting a therapeutic depot directly into the tumor site or the surgical resection cavity, it becomes possible to maintain high local concentrations of cytotoxic agents while minimizing systemic exposure. Among the various localized delivery platforms, polymeric hydrogels have distinguished themselves due to their structural similarities to the native extracellular matrix, their high water content, and their remarkable capacity for tissue integration. Hydrogels can encapsulate a diverse array of therapeutic cargo, ranging from small-molecule chemotherapeutics to large biological macromolecules such as proteins, nucleic acids, and monoclonal antibodies [4].

### **1.2 The Role of Biopolymers and Chitosan**

While synthetic polymers offer excellent control over mechanical properties and degradation kinetics, natural biopolymers have increasingly become the materials of choice for localized drug delivery due to their superior biocompatibility, inherent biodegradability, and lower propensity to induce chronic inflammatory responses. Among the diverse repertoire of natural polysaccharides, chitosan occupies a unique and highly advantageous position. Derived primarily from the alkaline deacetylation of chitin, which is abundantly found in the exoskeletons of crustaceans and the cell walls of fungi, chitosan is a linear polycationic biopolymer composed of randomly distributed beta-linked D-glucosamine and N-acetyl-D-glucosamine units. The primary structural feature that differentiates chitosan from other naturally occurring polysaccharides, such as hyaluronic acid or alginate, is the presence of primary amine groups along its polymeric backbone [5]. These amine groups impart a net positive charge to the molecule in mildly acidic environments, facilitating electrostatic interactions with negatively charged biological membranes, mucosal surfaces, and diverse therapeutic payloads. The cationic nature of chitosan is not merely a physicochemical curiosity; it is the fundamental basis for its remarkable mucoadhesive properties, its capacity to transiently open tight junctions in epithelial barriers, and its intrinsic ability to condense nucleic acids for gene delivery applications. In the context of cancer therapy, the polycationic structure of chitosan enables the creation of highly engineered, stimuli-responsive hydrogel networks. By carefully modulating the degree of deacetylation and the molecular weight of the polymer, researchers can fine-tune the physicochemical properties of the resulting hydrogel, dictating its swelling behavior, its mechanical stiffness, and its degradation profile. When introduced into the biological milieu, chitosan hydrogels are primarily degraded through the enzymatic action of naturally occurring lysozymes and chitinases, which cleave the glycosidic bonds to yield non-toxic oligosaccharides that are readily cleared by the renal system. Furthermore, chitosan is not biologically inert. Emerging evidence indicates that the polymer backbone itself possesses inherent immunomodulatory capabilities, capable of interacting with various pattern recognition receptors on the surface of innate immune cells [6]. This combination of stimuli-responsive behavior, excellent biocompatibility, and intrinsic immunoadjuvant activity positions chitosan-based hydrogels as uniquely powerful platforms for the development of next-generation, multifaceted cancer therapies.

## **2. Literature Review**

### **2.1 Stimuli-Responsive Hydrogels in Oncology**

The design of smart hydrogels that undergo abrupt physical or chemical transitions in response to specific environmental cues represents a major advancement in the field of controlled drug delivery. The tumor microenvironment exhibits a highly distinct biochemical and physiological profile compared to normal healthy tissues, providing a unique set of endogenous triggers that can be exploited for targeted therapy. One of the most universally recognized features of solid tumors is their acidic extracellular environment [7]. Due to the rapid proliferation of cancer cells and the structural

abnormalities of the tumor vasculature, the oxygen supply often falls short of the metabolic demand, leading to regions of severe hypoxia. To maintain their rapid growth, cancer cells shift their primary metabolic pathway from efficient oxidative phosphorylation to less efficient, but faster, aerobic glycolysis, a phenomenon famously known as the Warburg effect. This metabolic reprogramming results in the excessive production and extracellular secretion of lactic acid. Consequently, the extracellular pH of solid tumors frequently drops to values between 6.5 and 6.8, in stark contrast to the tightly regulated physiological pH of 7.4 found in normal tissues and the bloodstream [8]. Chitosan is ideally suited to exploit this pH gradient. The primary amine groups on the chitosan backbone possess a pKa value of approximately 6.5. In the neutral pH of healthy tissue, these amines remain largely deprotonated, allowing the polymer chains to maintain a relatively compact and stable configuration. However, upon entering the mildly acidic tumor microenvironment, the amine groups undergo rapid protonation. The resulting generation of widespread positive charges along the polymer chains induces strong electrostatic repulsion, causing the hydrogel network to undergo massive swelling or complete dissolution, thereby accelerating the release of the encapsulated chemotherapeutic cargo specifically at the tumor site. In addition to pH responsiveness, chitosan hydrogels have been extensively engineered to respond to thermal stimuli. The integration of thermosensitive polymers or the careful control of chitosan gelation kinetics allows for the development of injectable systems that exist as free-flowing liquids at room temperature but undergo rapid in situ sol-gel transitions upon reaching physiological body temperature [9]. This minimally invasive approach eliminates the need for surgical implantation, allowing the therapeutic depot to be precisely delivered to the tumor site via a simple syringe injection. Furthermore, the tumor microenvironment is characterized by high levels of reactive oxygen species and elevated concentrations of specific matrix metalloproteinases, which are secreted by cancer cells to degrade the surrounding extracellular matrix and facilitate tissue invasion and metastasis. Advanced chitosan hydrogels are increasingly being designed with dynamically cleavable crosslinkers that rupture in the presence of high reactive oxygen species concentrations or specific matrix metalloproteinases, adding an additional layer of targeted specificity to the drug release mechanism.

## **2.2 Chitosan as an Immunomodulatory Agent**

The traditional approach to cancer therapy has largely viewed the tumor as an isolated mass of rapidly dividing malignant cells. However, contemporary oncology recognizes the tumor as a complex, dynamic organ composed of cancer cells, an extracellular matrix, disorganized blood vessels, and a diverse array of infiltrating immune cells. This complex ecosystem is specifically engineered by the tumor to evade host immune surveillance [10]. Cancer cells actively secrete a milieu of immunosuppressive cytokines, such as transforming growth factor beta and interleukin-10, which collectively function to paralyze the cytotoxic function of T cells and natural killer cells. Concurrently, the tumor recruits and educates regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages to enforce an environment of profound immune tolerance. Tumor-associated macrophages, in particular, are typically polarized toward an alternative, tissue-repairing phenotype known as M2. Rather than attacking the cancer cells, these M2 macrophages actively promote tumor growth, angiogenesis, and extracellular matrix remodeling, directly facilitating metastasis and creating a physical barrier against conventional therapies [11]. Reversing this profound immunosuppression has become the primary goal of modern oncological immunology. In this context, chitosan hydrogels transition from being merely passive delivery vehicles to active therapeutic agents. The chemical structure of chitosan, particularly its repeating glucosamine units, bears structural similarities to various pathogen-associated molecular patterns. When innate immune cells, such as dendritic cells and macrophages, encounter chitosan within the tumor bed, pattern recognition receptors on their surface, including Toll-like receptor 4 and the mannose receptor, bind to the polymer [12]. This binding event triggers an intracellular signaling cascade that initiates a powerful localized inflammatory response. For dendritic cells, this interaction promotes maturation, upregulating the expression of major histocompatibility complex molecules and crucial co-stimulatory surface markers such as CD80 and CD86. Mature dendritic cells are then capable of capturing tumor antigens released by dying cancer cells, migrating to the draining lymph nodes, and presenting these antigens to naive T cells, thereby

initiating a robust, systemic, and highly specific adaptive anti-tumor immune response [13]. Simultaneously, the presence of chitosan within the tumor microenvironment has been documented to repolarize tumor-associated macrophages from the pro-tumorigenic M2 phenotype back to the anti-tumorigenic M1 phenotype. The classically activated M1 macrophages begin to secrete pro-inflammatory cytokines, including tumor necrosis factor alpha and interferon gamma, and produce high levels of nitric oxide and reactive oxygen species, actively participating in the direct phagocytosis and destruction of cancer cells. When chitosan hydrogels are utilized to deliver traditional cytotoxic drugs, a powerful synergistic loop is created. The chemotherapeutic agent induces immunogenic cell death in the cancer cells, causing them to release damage-associated molecular patterns and a wealth of tumor-specific antigens. Concurrently, the chitosan scaffold provides the necessary adjuvant signal to the local immune cells, ensuring that these released antigens are efficiently captured and processed, effectively transforming the dying tumor into an in situ personalized vaccine [14]. This dual functionality holds immense promise for preventing tumor recurrence and eradicating distant metastatic lesions, an outcome that is notoriously difficult to achieve with conventional monotherapies [15].

### 3. Methodology and System Design

#### 3.1 Synthesis Strategies for Chitosan Hydrogels

The rational design and synthesis of chitosan hydrogels require a deep understanding of polymer chemistry and the specific biological requirements of the intended application. The primary objective is to create a three-dimensional network that provides adequate mechanical integrity to persist at the injection site while retaining the necessary porosity and responsiveness to release the therapeutic payload over a desired timeframe. Hydrogel synthesis generally falls into two broad categories: physical crosslinking and chemical crosslinking. Physical crosslinking relies on reversible, non-covalent interactions between the polymer chains. These interactions can include electrostatic forces, hydrogen bonding, and hydrophobic associations. The most prevalent method for physically crosslinking chitosan involves the addition of multivalent anionic molecules, such as sodium tripolyphosphate or beta-glycerophosphate. When these negatively charged crosslinkers are introduced to an acidic solution of chitosan, strong ionic bridges form between the negatively charged phosphate groups and the positively charged protonated amine groups of the chitosan backbone [16]. Physical crosslinking offers the distinct advantage of avoiding potentially toxic chemical reagents, ensuring excellent biocompatibility. However, physically crosslinked hydrogels often suffer from inferior mechanical strength and rapid degradation rates in vivo, which may limit their utility for long-term sustained release applications.

**Table 1: Synthesis Methods for Chitosan Hydrogels**

| Crosslinking Method   | Primary Interaction Mechanism                      | Distinct Advantages and Characteristics         |
|-----------------------|----------------------------------------------------|-------------------------------------------------|
| Physical Crosslinking | Electrostatic forces and hydrogen bonding          | Excellent biocompatibility, simple preparation  |
| Chemical Crosslinking | Covalent bonds via glutaraldehyde or genipin       | High mechanical stability, tunable degradation  |
| Dynamic Covalent      | Schiff base formation between amines and aldehydes | Self-healing properties, pH-responsive cleavage |

To overcome the mechanical limitations of physical gels, chemical crosslinking strategies are frequently employed. Chemical crosslinking involves the formation of strong, permanent covalent bonds between the chitosan chains, typically mediated by small molecule crosslinkers. Historically, glutaraldehyde was widely used for this purpose; however, its inherent cytotoxicity and potential to induce severe local inflammation have largely precluded its use in biomedical applications. Consequently, researchers have shifted toward natural, low-toxicity crosslinking agents such as genipin, an aglycone derived from the gardenia fruit. Genipin reacts with the primary amine groups of

chitosan to form a structurally stable, dark blue fluorescent hydrogel network with excellent biocompatibility and significantly enhanced mechanical toughness [17]. In addition to static covalent bonds, recent methodological advancements have focused on the incorporation of dynamic covalent chemistry. The formation of Schiff base linkages, resulting from the reaction between the primary amines of chitosan and aldehyde-functionalized polymers, represents a highly sophisticated approach [18]. Schiff base bonds are inherently dynamic and reversible; they maintain structural stability at physiological pH but undergo rapid hydrolysis in the acidic environment of the tumor, providing a chemically elegant mechanism for achieving highly specific, stimuli-responsive drug release and structural degradation.

Figure 1: Mechanism of Chitsoan Hydrogels




Figure 1: Mechanism of Chitosan Hydrogels

### 3.2 Evaluation of Stimuli-Responsive Mechanisms

The comprehensive evaluation of chitosan-based smart hydrogels necessitates a rigorous and multifaceted analytical methodology, transitioning from fundamental physicochemical characterization to complex in vitro and in vivo biological assessments. The initial phase of evaluation typically involves a detailed rheological analysis to quantify the mechanical properties of the hydrogel network. By utilizing a rotational rheometer, researchers measure the storage modulus and the loss modulus across various frequencies, temperatures, and strain rates. These measurements are critical for determining the injectability of the formulation, ensuring that the hydrogel possesses a sufficiently low viscosity to pass through a standard hypodermic needle while rapidly recovering its structural integrity upon deposition in the target tissue. Furthermore, the swelling and degradation kinetics of the hydrogels must be systematically evaluated in buffers that accurately mimic the physiological conditions of healthy tissue versus the targeted tumor microenvironment. For the analysis of drug release profiles, the hydrogel loaded with a specific therapeutic agent is typically incubated in release media of varying pH, such as pH 7.4 to simulate blood plasma and pH 6.5 to simulate the acidic extracellular fluid of the tumor. Aliquots of the release media are sampled at predefined time intervals, and the concentration of the released drug is quantified utilizing high-performance liquid chromatography or ultraviolet-visible spectroscopy. The resulting cumulative release curves are then subjected to rigorous mathematical modeling. By applying mathematical frameworks such as the Korsmeyer-Peppas model, where the fractional release of the drug is proportional to time raised to the release exponent, researchers can elucidate the fundamental mechanisms driving the release process, distinguishing between simple Fickian diffusion of the drug through the porous network and release dictated by the physical swelling and eventual enzymatic erosion of the polymer matrix itself. Beyond physicochemical characterization, the evaluation of immunomodulatory efficacy requires complex cellular assays. To quantify the activation of innate immune cells, primary bone marrow-derived dendritic cells or established macrophage cell lines are co-cultured with the chitosan hydrogels or their degradation products.

Following a specified incubation period, the cells are harvested and subjected to flow cytometry to meticulously quantify the surface expression of vital activation markers and costimulatory molecules. Simultaneously, the culture supernatant is analyzed using enzyme-linked immunosorbent assays to detect and measure the concentration of secreted pro-inflammatory and anti-inflammatory cytokines, providing a comprehensive profile of the immunological cascade initiated by the hydrogel [19]. For ultimate validation, these systems are advanced to *in vivo* testing using syngeneic murine tumor models, such as the B16F10 melanoma model or the 4T1 breast cancer model. These models possess intact, functional immune systems, which are absolutely essential for evaluating the complex interplay between the localized drug release, the adjuvant properties of the chitosan scaffold, and the subsequent activation of a systemic anti-tumor immune response.

#### 4. Results and Discussion

##### 4.1 Efficacy of Targeted Drug Delivery

The aggregated results from recent *in vivo* studies consistently demonstrate that stimuli-responsive chitosan hydrogels significantly outperform both free drug administration and non-responsive delivery systems in terms of overall therapeutic efficacy. When chemotherapeutic agents, such as doxorubicin or paclitaxel, are administered systemically in their free form, the vast majority of the dose is cleared by the hepatic and renal systems, with only a minute fraction reaching the tumor site. In stark contrast, the peritumoral or intratumoral injection of a smart chitosan hydrogel depot localizes the entire therapeutic payload at the site of the disease. Experimental data frequently show that the concentration of the chemotherapeutic drug within the tumor tissue remains at therapeutically relevant levels for extended periods, often ranging from several days to multiple weeks, depending on the specific crosslinking density and degradation rate of the formulation [20].

Table 2: Comparative Efficacy of Chitosan Hydrogel Systems

| Delivery System Type   | Drug Retention Time in Tumor | Tumor Growth Inhibition Rate |
|------------------------|------------------------------|------------------------------|
| Free Systemic Drug     | Less than 24 hours           | Low to Moderate              |
| Non-responsive Gel     | 3 to 5 days                  | Moderate                     |
| pH-Responsive Chitosan | 10 to 14 days                | High                         |

The implementation of pH-responsive linkages, such as the dynamic Schiff base, provides an exceptional degree of spatiotemporal control. In physiological environments, the baseline release of the encapsulated drug is remarkably low, which serves to drastically minimize the systemic toxicity and off-target effects typically associated with conventional chemotherapy. However, upon exposure to the acidic tumor microenvironment, the hydrogel network rapidly undergoes localized swelling and accelerated structural degradation. This stimuli-responsive behavior results in a sudden, targeted burst release of the cytotoxic agent directly adjacent to the malignant cells, effectively maximizing the local therapeutic index while sparing surrounding healthy tissues. Volumetric measurements of tumor progression in murine models consistently reveal that this sustained, targeted delivery approach yields profound tumor growth inhibition, and in several optimized formulations, leads to the complete eradication of established solid tumors without the severe weight loss or systemic organ toxicity observed in control groups receiving standard intravenous chemotherapy regimens [21].

##### 4.2 Immunological Responses and Tumor Microenvironment Modulation

The most compelling results emerging from the evaluation of chitosan hydrogels extend beyond their capabilities as simple physical delivery vehicles, highlighting their active role in reshaping the immunological landscape of the tumor microenvironment. Histological analysis and immunofluorescence staining of tumor tissues excised following treatment with chitosan-based formulations reveal striking alterations in the composition and spatial distribution of infiltrating immune cells. Tumors treated with the combined chemo-immunotherapy hydrogels exhibit a massive influx of cytotoxic CD8 positive T cells compared to untreated controls. This robust infiltration of effector cells is accompanied by a concurrent and highly significant reduction in the localized populations of immunosuppressive regulatory T cells and myeloid-derived suppressor cells [22]. Furthermore, detailed flow cytometric analysis of the tumor-associated macrophage populations

provides definitive in vivo confirmation of chitosan's potent repolarizing effects. Within the treated tumor beds, researchers observe a dramatic shift in the macrophage ratio, characterized by a substantial decrease in M2-like markers and a corresponding surge in M1-like markers. This active repolarization functionally transforms the extracellular environment from one that nurtures tumor growth and metastasis to one that is inherently hostile and highly inflammatory. The synergistic efficacy of combining the cytotoxic action of encapsulated drugs with the inherent adjuvant properties of the chitosan backbone is particularly evident in survival studies and rechallenge experiments. In numerous studies utilizing syngeneic murine models, subjects that achieve complete tumor regression following hydrogel treatment frequently demonstrate robust immunological memory. When these surviving subjects are subsequently reinoculated with the same cancer cells weeks or months later, their immune systems rapidly recognize and eradicate the new malignant cells, preventing tumor establishment. This profound systemic protection indicates that the localized intervention has successfully generated a durable, adaptive immune response capable of circulating throughout the body, offering immense potential for controlling micrometastatic disease and ensuring long-term patient survival.

## **5. Conclusion**

### **5.1 Summary of Findings**

The development and rigorous scientific validation of stimuli-responsive chitosan hydrogels represent a critical paradigm shift in the multidisciplinary field of oncological treatment. By moving away from indiscriminate systemic therapies and embracing highly localized, biologically responsive platforms, researchers have established a framework for delivering unprecedented concentrations of therapeutic agents directly to the site of malignancy. The unique structural characteristics of the chitosan biopolymer, particularly its primary amine functional groups, allow for seamless integration into sophisticated chemical networks capable of reacting dynamically to the unique acidic and enzymatic signatures of the tumor microenvironment. This environmental responsiveness ensures that the release of potent chemotherapeutics is tightly restricted to the specific region of the pathology, vastly improving the therapeutic index and virtually eliminating the severe systemic toxicities that have long plagued conventional cancer care. Beyond the mechanics of drug delivery, the intrinsic immunomodulatory properties of chitosan elevate these hydrogels from passive carriers to active therapeutic components. The ability of the biopolymer to engage specific pattern recognition receptors, stimulate the maturation of dendritic cells, and force the repolarization of tumor-associated macrophages effectively dismantles the profound immunosuppressive shield erected by solid tumors. This dual-action approach, simultaneously inducing localized cell death and initiating a systemic, highly specific adaptive immune response, addresses the fundamental biological complexities of the disease in a manner that single-modality treatments simply cannot achieve.

### **5.2 Future Directions**

Despite the overwhelming preclinical success demonstrated across diverse experimental models, the journey toward the widespread clinical integration of smart chitosan hydrogels requires continued rigorous investigation. A primary challenge moving forward is the inherent natural variability associated with biologically sourced polymers. Achieving precise batch-to-batch consistency in the molecular weight and the degree of deacetylation of chitosan is absolutely critical for satisfying the stringent regulatory requirements mandated by global health authorities. Furthermore, scaling up the complex synthetic processes required for creating dual-responsive and dynamic covalent networks, while maintaining absolute sterility and eliminating any trace endotoxin contamination, will necessitate significant advancements in pharmaceutical manufacturing technologies. Future research must also prioritize large-scale, long-term studies involving large animal models to better approximate the immense complexity of human tumor physiology, particularly regarding the density of the extracellular matrix and the precise architecture of the human immune system. Ultimately, the integration of cutting-edge diagnostic imaging agents into the hydrogel matrix may pave the way for true theranostic platforms, allowing clinicians to simultaneously treat the disease and monitor the localized biological response in real time, ushering in a new era of highly personalized and exceptionally precise cancer immunotherapy [23].

## References

- Xu, X., Bowtell, J., Young, W. R., Fong, D. T., & Williams, G. K. (2025). Distinct patterns in neuromuscular adaptation to repeated perturbations in chronic ankle instability. *Journal of NeuroEngineering and Rehabilitation*.
- Tang, Y., Luo, Z., Zhao, X., Zhang, Y., Sun, M., & Zhang, J. (2026). Traditional Chinese Medicine as an Integrative Adjunct in Oncology Perioperative Practice: Analgesia, Immune Modulation, and Translational Challenges. *Medicine Bulletin*, 2(2), 184-204.
- Li, Y., Liao, X., Tang, S., Wang, Q., Lin, H., Yu, X., ... & Zhong, T. (2025). Potential Therapeutic Targets for Androgenetic Alopecia (AGA) in Obese Individuals as Revealed by a Gut Microbiome Analysis: A Mendelian Randomization Study. *Nutrients*, 17(11), 1892.
- Xiao, Y., Xiao-yue, Z., Yue, W., Ruo-tao, L., Xiang-jie, L., Xing-yuan, W., ... & Zhen-yi, J. (2022). Use of computed tomography for the diagnosis of surgical sarcopenia: Review of recent research advances. *Nutrition in Clinical Practice*, 37(3), 583-593.
- Zhao, Haoyu, et al. "Dynamictrl: Rethinking the basic structure and the role of text for high-quality human image animation." *arXiv preprint arXiv:2503.21246* (2025).
- Banerjee, S., Kwaan, M. R., Wu, Y., Ren, Y., & Xirasagar, S. (2023). Ostomy Surgery for Patients with Large Bowel Obstruction in the Modern Era: a Nationwide Inpatient Sample Study. *Journal of Gastrointestinal Surgery*, 27(3), 585-589.
- Kwaan, M. R., Wu, Y., Ren, Y., & Xirasagar, S. (2022). Prompt intervention in large bowel obstruction management: A Nationwide Inpatient Sample analysis. *The American Journal of Surgery*, 224(5), 1262-1266.
- Chen, X., Cheng, Q., Gong, F., & Zheng, H. (2025). Protein Post-Translational Modification-Mediated Control of Type I Interferon Cascade Signaling. *Medicine Bulletin*, 1(1), 37-59.
- Lu, Y., Shi, T., Liu, W., Shang, D., Liu, X., Wang, Q., ... & Duan, X. (2025). Supramonomer-Based Glyco-Cationic Nanoparticles With GSH Depletion-Enhanced Drug/Gene Co-Delivery for Combination Therapy. *Medicine Bulletin*, 1(2), 171-181.
- Peng, Q., Zheng, C., & Chen, C. (2023). Source-free domain adaptive human pose estimation. In *Proceedings of the IEEE/CVF International Conference on Computer Vision* (pp. 4826-4836).
- Chu, Y. B., Li, J., Jia, P., Cui, J., Zhang, R., Kang, X., ... & Zhang, S. (2021). Irf1-and Egr1-activated transcription plays a key role in macrophage polarization: A multiomics sequencing study with partial validation. *International Immunopharmacology*, 99, 108072.
- Wu, Y., Chen, Z., Lee, J., Zengin, G., & Li, M. Y. (2026). Circular RNAs: Epigenetic Puppeteers Pulling the Strings of Cancer Pathogenesis. *Medicine Bulletin*.
- Zhao, H., Wang, Q., Zhan, G., Min, W., Zou, Y., & Cui, S. (2022). Need only one more point (NOOMP): Perspective adaptation crowd counting in complex scenes. *IEEE Transactions on Multimedia*, 25, 1414-1426.
- Lopez, R., Regier, J., Cole, M. B., Jordan, M. I., & Yosef, N. (2018). Deep generative modeling for single-cell transcriptomics. *Nature Methods*, 15(12), 1053-1058.
- Yang, Y., Lin, Y. T., Li, G., Zhong, Y., Xu, Q., & Cai, J. J. (2023). Interpretable modeling of time-resolved single-cell gene-protein expression with CrossmodalNet. *Briefings in Bioinformatics*, 24(6), bbad342.
- Cai, Lie, et al. "Deep learning model for breast shear wave elastography to improve breast cancer diagnosis (INSPIRED 006): An international, multicenter analysis." *Journal of Clinical Oncology* 43.32 (2025): 3482-3493.
- Zhang, Y., He, Y., Shao, Y., Yao, Z., Xu, H., Dong, J., ... & Dong, Z. (2026, May). Chromouvqa: Benchmarking vision-language models under chromatic camouflaged images. In *ICASSP 2026-2026 IEEE International Conference on Acoustics, Speech and Signal Processing (ICASSP)* (pp. 12777-12781). IEEE.
- Guo, Hanzhong, et al. "Leveraging verifier-based reinforcement learning in image editing." *arXiv preprint arXiv:2604.27505* (2026).

- Xie, C., Zhu, D., Wang, Z., Zhang, H., & Wei, Z. (2026). Compliance-Aware Discharge Agent for Auditable ICU Discharge Planning: A Pilot Feasibility Study Using Structured eICU Records. Available at SSRN 6429758.
- Xie, C., Zhu, D., Wang, Z., Zhang, H., & Wei, Z. (2026). Explainable AI for Mental Health Detection from Social Media: A Comparative Study of Traditional Machine Learning and a Large Language Model. Available at SSRN 6429778.
- Yu, X., Zhang, Y., Yao, Y., Cho, W. C., & Shang, A. (2025). Biofilm-mediated immune dysregulation in chronic pulmonary diseases: mechanisms and clinical implications. *Frontiers in Microbiology*, 16, 1736384.
- Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., et al. (2021). Highly accurate protein structure prediction with AlphaFold. *Nature*, 596(7873), 583–589.
- Xu, X., Bowtell, J., Young, W. R., Fong, D. T., & Williams, G. K. (2026). Increased common corticospinal input during eyes-closed unilateral stance in people with chronic ankle instability. *Scientific Reports*.